This idea led to studies of the functions of MSCs derived from MM patients (MM-derived MSCs) compared to those of healthy individuals; it was suggested that MSCs from myeloma patients exhibit defective functions [68–70]: MM-derived MSCs were reported to exhibit decreased colony-forming unit number [70], growth impairment [70], reduced osteogenic differentiation [68], and increased IL-6 secretion [68, 70]. This evidence concerns the gene IL6 and plasma cell myeloma.